Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 4 (2007), Issue 8 (August)

1. Lipids and lactate in human immunodeficiency virus-1 infected pregnancies with or without protease inhibitor-based therapy.
   Obstet Gynecol, 110(2): 391-7. [Abstract] [Full-text]
2. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status.
   J Natl Cancer Inst, 99(15): 1152-61. [Abstract] [Full-text]
3. Phase 1/2 clinical trial of interferon alpha2b and weekly liposome-encapsulated all-trans retinoic acid in patients with advanced renal cell carcinoma.
   J Immunother (1997), 30(6): 655-62. [Abstract] [Full-text]
4. Language barriers to prescriptions for patients with limited English proficiency: a survey of pharmacies.
   Pediatrics, 120(2): e225-35. [Abstract] [Full-text]
5. Targeting of retinal axons requires the metalloproteinase ADAM10.
   J Neurosci, 27(31): 8448-56. [Abstract] [Full-text]
6. Iodopovidone pleurodesis does not effect thyroid function in normal adults.
   Interact Cardiovasc Thorac Surg, 6(4): 563-4. [Abstract] [Full-text]
7. Cefuroxime as antibiotic prophylaxis in coronary artery bypass grafting surgery.
   Interact Cardiovasc Thorac Surg, 6(4): 442-6. [Abstract] [Full-text]
8. Hepatitis C virus quasispecies in HIV-infected women: role of injecting drug use and highly active antiretroviral therapy (HAART).
   Hepatology, 46(2): 359-70. [Abstract] [Full-text]
9. Local recurrence and local control of non-metastatic osteosarcoma of the extremities: a 27-year experience in a single institution.
   J Surg Oncol, 96(2): 118-23. [Abstract] [Full-text]
10. Prevention of surgical site infection after breast cancer surgery by targeted prophylaxis antibiotic in patients at high risk of surgical site infection.
    J Surg Oncol, 96(2): 124-9. [Abstract] [Full-text]
11. Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development.
    Pharm Res, 24(9): 1745-58. [Abstract] [Full-text]
12. Blood-brain barrier transport of therapeutics via receptor-mediation.
    Pharm Res, 24(9): 1759-71. [Abstract] [Full-text]
13. Drug targeting to the brain.
    Pharm Res, 24(9): 1733-44. [Abstract] [Full-text]
14. Enhanced intercellular retention activity of novel pH-sensitive polymeric micelles in wild and multidrug resistant MCF-7 cells.
    Pharm Res, 24(9): 1618-27. [Abstract] [Full-text]
15. Progression after docetaxel-based chemotherapy in androgen-independent prostate cancer.
    BJU Int, 100(3): 533-5. [Abstract] [Full-text]
16. Therapeutic integration of c-myc and bcl-2 antisense molecules with docetaxel in a preclinical model of hormone-refractory prostate cancer.
    Prostate, 67(13): 1475-85. [Abstract] [Full-text]
17. Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women.
    BMJ, 335(7613): 239. [Abstract] [Full-text]
18. Fixed-dose combinations improve medication compliance: a meta-analysis.
    Am J Med, 120(8): 713-9. [Abstract] [Full-text]
19. Acute reperfusion therapy in ST-elevation myocardial infarction from 1994-2003.
    Am J Med, 120(8): 693-9. [Abstract] [Full-text]
20. Adjuvant therapy for pancreas cancer: advances and controversies.
    Semin Oncol, 34(4): 321-6. [Abstract] [Full-text]
21. Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201.
    Blood, 110(4): 1105-11. [Abstract] [Full-text]
22. Covalently linked DNA/protein multilayered film for controlled DNA release.
    J Colloid Interface Sci, 314(1): 80-8. [Abstract] [Full-text]
23. A phase I and pharmacokinetic study of irofulven and capecitabine administered every 2 weeks in patients with advanced solid tumors.
    Invest New Drugs, 25(5): 453-62. [Abstract] [Full-text]
24. The efficacy of hybrid chemotherapy with intravenous oxaliplatin and folinic acid and intra-hepatic infusion of 5-fluorouracil in patients with colorectal liver metastases: a phase II study.
    Invest New Drugs, 25(5): 479-85. [Abstract] [Full-text]
25. Docetaxel-ifosfamide combination in patients with HER2-non-overexpressing advanced breast cancer failing prior anthracyclines.
    Invest New Drugs, 25(5): 463-70. [Abstract] [Full-text]
26. Nucleoside reverse-transcriptase inhibitor dosing errors in an outpatient HIV clinic in the electronic medical record era.
    Clin Infect Dis, 45(5): 658-61. [Abstract] [Full-text]
27. Immunologic and clinical responses to highly active antiretroviral therapy in patients with HIV infection aged >50 years.
    Clin Infect Dis, 45(5): 654-7. [Abstract] [Full-text]
28. Response to measles, mumps, and rubella revaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy.
    Clin Infect Dis, 45(5): 637-42. [Abstract] [Full-text]
29. Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion.
    Clin Infect Dis, 45(5): 624-32. [Abstract] [Full-text]
30. Risk of recurrent nontyphoid Salmonella bacteremia in HIV-infected patients in the era of highly active antiretroviral therapy and an increasing trend of fluoroquinolone resistance.
    Clin Infect Dis, 45(5): e60-7. [Abstract] [Full-text]
31. Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes.
    Proc Natl Acad Sci U S A, 104(32): 12982-7. [Abstract] [Full-text]
32. Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-alpha.
    Cancer, 110(4): 801-8. [Abstract] [Full-text]
33. Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site.
    Cancer, 110(4): 770-5. [Abstract] [Full-text]
34. First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer.
    Cancer, 110(4): 752-8. [Abstract] [Full-text]
35. Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million patients.
    J Clin Oncol, 25(23): 3462-8. [Abstract] [Full-text]
36. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803.
    J Clin Oncol, 25(23): 3456-61. [Abstract] [Full-text]
37. Receipt of appropriate primary breast cancer therapy and adjuvant therapy are not associated with obesity in older women with access to health care.
    J Clin Oncol, 25(23): 3428-36. [Abstract] [Full-text]
38. A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer.
    BMC Cancer, 7: 142. [Abstract] [Full-text]
39. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.
    J Clin Oncol, 25(23): 3495-502. [Abstract] [Full-text]
40. Regional changes in hormone therapy use and breast cancer incidence in California from 2001 to 2004.
    J Clin Oncol, 25(23): 3437-9. [Abstract] [Full-text]
41. Effect of preprinted order form on epoetin alfa prescribing.
    Am J Health Syst Pharm, 64(16): 1732-8. [Abstract] [Full-text]
42. Pharmacist-conducted medication reconciliation in an emergency department.
    Am J Health Syst Pharm, 64(16): 1720-3. [Abstract] [Full-text]
43. Concurrent carboplatin and paclitaxel with pelvic radiation therapy in the primary treatment of cervical cancer.
    Am J Obstet Gynecol, 197(2): 205.e1-5; discussion 205.e5-7. [Abstract] [Full-text]
44. Long-term use of postmenopausal estrogen and progestin hormone therapies and the risk of endometrial cancer.
    Am J Obstet Gynecol, 197(2): 139.e1-7. [Abstract] [Full-text]
45. Body composition during treatment with conjugated estrogens with and without medroxyprogesterone acetate: analysis of the women's Health, Osteoporosis, Progestin, Estrogen (HOPE) trial.
    Am J Obstet Gynecol, 197(2): 137.e1-7. [Abstract] [Full-text]
46. Framework for teaching pharmacology to prepare graduate nurse for prescribing in New Zealand.
    Nurse Educ Pract, 7(5): 348-53. [Abstract] [Full-text]
47. Dendrimers and their applications in immunoassays and clinical diagnostics.
    Biotechnol Appl Biochem, 48: 1-9. [Abstract] [Full-text]
48. Barriers to obtaining waivers to prescribe buprenorphine for opioid addiction treatment among HIV physicians.
    J Gen Intern Med, 22(9): 1325-9. [Abstract] [Full-text]
49. Ischemic stroke, aortic dissection, and thrombolytic therapy--the importance of basic clinical skills.
    J Gen Intern Med, 22(9): 1370-2. [Abstract] [Full-text]
50. Implicit bias among physicians and its prediction of thrombolysis decisions for black and white patients.
    J Gen Intern Med, 22(9): 1231-8. [Abstract] [Full-text]
51. Photodynamic therapy reduces intimal hyperplasia in prosthetic vascular bypass grafts in a pig model.
    Eur J Vasc Endovasc Surg, 34(3): 333-9. [Abstract] [Full-text]
52. Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a lung cancer Galician group phase II study.
    Cancer Chemother Pharmacol, 60(5): 725-32. [Abstract] [Full-text]
53. Synergistic interaction between tetrandrine and chemotherapeutic agents and influence of tetrandrine on chemotherapeutic agent-associated genes in human gastric cancer cell lines.
    Cancer Chemother Pharmacol, 60(5): 703-11. [Abstract] [Full-text]
54. Water-soluble pH-responsive dendritic core-shell nanocarriers for polar dyes based on poly(ethylene imine).
    Macromol Biosci, 7(8): 968-74. [Abstract] [Full-text]
55. Mitochondriotropics: a review of their mode of action, and their applications for drug and DNA delivery to mammalian mitochondria.
    J Control Release, 121(3): 125-36. [Abstract] [Full-text]
56. Nano-ferrosponges for controlled drug release.
    J Control Release, 121(3): 181-9. [Abstract] [Full-text]
57. Controlled release of PEI/DNA complexes from mannose-bearing chitosan microspheres as a potent delivery system to enhance immune response to HBV DNA vaccine.
    J Control Release, 121(3): 200-7. [Abstract] [Full-text]
58. Complexation and release of doxorubicin from its complexes with pluronic P85-b-poly(acrylic acid) block copolymers.
    J Control Release, 121(3): 137-45. [Abstract] [Full-text]
59. Brain delivery of vasoactive intestinal peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration.
    J Control Release, 121(3): 156-67. [Abstract] [Full-text]
60. Pharmacokinetic and pharmacodynamic studies following percutaneous absorption of erythropoietin micropiles to rats.
    J Control Release, 121(3): 176-80. [Abstract] [Full-text]
61. Optimization of (1,2-diamino-cyclohexane)platinum(II)-loaded polymeric micelles directed to improved tumor targeting and enhanced antitumor activity.
    J Control Release, 121(3): 146-55. [Abstract] [Full-text]
62. Replacement of intestinal mucosa with urothelium in rat augmented bladders using intravesical photodynamic therapy with 5-aminolaevulinic acid.
    J Urol, 178(3): 1108-12. [Abstract] [Full-text]
63. Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers.
    J Urol, 178(3): 844-8; discussion 848. [Abstract] [Full-text]
64. Membrane-coated fiber array approach for predicting skin permeability of chemical mixtures from different vehicles.
    Toxicol Sci, 99(1): 153-61. [Abstract] [Full-text]
65. Adenovirus BMP2-induced osteogenesis in combination with collagen carriers.
    Biomaterials, 28(30): 4469-79. [Abstract] [Full-text]
66. Cholesterol transport from liposomal delivery vehicles.
    Biomaterials, 28(29): 4311-20. [Abstract] [Full-text]
67. Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors.
    Clin Cancer Res, 13(16): 4849-57. [Abstract] [Full-text]
68. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
    J Natl Cancer Inst, 99(16): 1232-9. [Abstract] [Full-text]
69. Immunogenicity of influenza virus vaccine is increased by anti-gal-mediated targeting to antigen-presenting cells.
    J Virol, 81(17): 9131-41. [Abstract] [Full-text]
70. Comparison of clinical and economic outcomes of two antibiotic prophylaxis regimens for sternal wound infection in high-risk patients following coronary artery bypass grafting surgery: a prospective randomised double-blind controlled trial.
    Heart, 93(9): 1126-33. [Abstract] [Full-text]
71. Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies.
    J Clin Oncol, 25(24): 3753-8. [Abstract] [Full-text]
72. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1.
    J Clin Oncol, 25(24): 3732-8. [Abstract] [Full-text]
73. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer.
    J Clin Oncol, 25(24): 3719-25. [Abstract] [Full-text]
74. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience.
    J Clin Oncol, 25(24): 3699-704. [Abstract] [Full-text]
75. Photodynamic therapy for cutaneous verrucous carcinoma.
    J Am Acad Dermatol, 57(3): 516-9. [Abstract] [Full-text]
76. Pyridoxine and pyridostigmine treatment in vincristine-induced neuropathy.
    Pediatr Hematol Oncol, 24(6): 447-52. [Abstract] [Full-text]
77. Pharmacokinetics of doxorubicin and etoposide in a morbidly obese pediatric patient.
    Pediatr Hematol Oncol, 24(6): 437-45. [Abstract] [Full-text]
78. Clinical characteristics and treatment results of pediatric B-cell non-Hodgkin lymphoma patients in a single center.
    Pediatr Hematol Oncol, 24(6): 417-30. [Abstract] [Full-text]
79. Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin.
    Pediatr Hematol Oncol, 24(6): 403-8. [Abstract] [Full-text]
80. Antibiotic use for emergency department patients with upper respiratory infections: prescribing practices, patient expectations, and patient satisfaction.
    Ann Emerg Med, 50(3): 213-20. [Abstract] [Full-text]
81. Matrix metalloproteinases in human choroidal neovascular membranes excised following verteporfin photodynamic therapy.
    Br J Ophthalmol, 91(9): 1183-9. [Abstract] [Full-text]
82. Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials.
    Leukemia, 21(9): 2020-4. [Abstract] [Full-text]
83. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial.
    Leukemia, 21(9): 1907-14. [Abstract] [Full-text]
84. Short schedule of cisplatin and vinorelbine: a dose-finding study in non-small-cell lung cancer.
    Oncology, 71(3): 229-36. [Abstract] [Full-text]
85. A dose escalation study of gemcitabine plus pemetrexed administered biweekly in patients with solid tumors.
    Oncology, 71(3): 197-203. [Abstract] [Full-text]
86. Failure to weigh patients in hospital: a medication safety risk.
    Intern Med J, 37(9): 647-50. [Abstract] [Full-text]
87. Targeting polyamine metabolism: a viable therapeutic/preventative solution for cancer?
    Expert Opin Pharmacother, 8(13): 2109-16. [Abstract] [Full-text]
88. Discontinuity and disaster: gaps and the negotiation of culpability in medication delivery.
    J Law Med Ethics, 35(3): 463-70. [Abstract] [Full-text]
89. Acute kidney injury, hyperosmolality and metabolic acidosis associated with lorazepam.
    Nat Clin Pract Nephrol, 3(9): 515-20. [Abstract] [Full-text]
90. Supplemental oxygen, but not supplemental crystalloid fluid, increases tissue oxygen tension in healthy and anastomotic colon in pigs.
    Anesth Analg, 105(3): 773-9. [Abstract] [Full-text]
91. A comparison of mortality, myocardial infarction, and repeated revascularization for sirolimus-eluting and paclitaxel-eluting coronary stents.
    Am Heart J, 154(3): 545-53. [Abstract] [Full-text]
92. A randomized comparison of sirolimus-eluting stent implantation with zotarolimus-eluting stent implantation for the treatment of total coronary occlusions: rationale and design of the PRImary Stenting of Occluded Native coronary arteries III (PRISON III) study.
    Am Heart J, 154(3): 432-5. [Abstract] [Full-text]
93. Applying drug-eluting stents in clinical practice.
    Am J Cardiol, 100(5): 25K-31K. [Abstract] [Full-text]
94. Understanding the drug-eluting stent trials.
    Am J Cardiol, 100(5): 17K-24K. [Abstract] [Full-text]
95. Comparison of usefulness of sodium bicarbonate versus sodium chloride to prevent contrast-induced nephropathy in patients undergoing an emergent coronary procedure.
    Am J Cardiol, 100(5): 781-6. [Abstract] [Full-text]
96. Photodynamic effects of SIM01, a new sensitizer, on experimental brain tumors in rats.
    Surg Neurol, 68(3): 255-63; discussion 263. [Abstract] [Full-text]
97. Combination of thalidomide and cisplatin in an head and neck squamous cell carcinomas model results in an enhanced antiangiogenic activity in vitro and in vivo.
    Int J Cancer, 121(8): 1697-704. [Abstract] [Full-text]
98. Prophylactic treatment of a small child with severe factor VII deficiency using repeat dosing from a single vial of recombinant activated factor VII.
    Pediatr Blood Cancer, 49(5): 736-9. [Abstract] [Full-text]
99. Hope is forked: hope, loss, treatments, and AIDS dementia.
    Qual Health Res, 17(7): 866-72. [Abstract] [Full-text]
100. Effect of a robotic prescription-filling system on pharmacy staff activities and prescription-filling time.
     Am J Health Syst Pharm, 64(17): 1832-9. [Abstract] [Full-text]
101. Lenalidomide in the treatment of multiple myeloma.
     Am J Health Syst Pharm, 64(17): 1799-807. [Abstract] [Full-text]
102. Long-term outcome after thrombolysis in telemedical stroke care.
     Neurology, 69(9): 898-903. [Abstract] [Full-text]
103. Coated microneedles for drug delivery to the eye.
     Invest Ophthalmol Vis Sci, 48(9): 4038-43. [Abstract] [Full-text]
104. Thermal sensitization through ROS modulation: a strategy to improve the efficacy of hyperthermic intraperitoneal chemotherapy.
     Surgery, 142(3): 384-92. [Abstract] [Full-text]
105. Targeting individual hemodynamics to maintain renal perfusion during pneumoperitoneum in a porcine model.
     Surgery, 142(3): 350-6. [Abstract] [Full-text]
106. Real time observation of diffusion and bioaffinity binding processes in single polyelectrolyte-coated microcapsules: a fluorescence-based approach.
     Colloids Surf B Biointerfaces, 60(1): 125-30. [Abstract] [Full-text]
107. Analysis of Tween based microemulsion in the presence of TB drug rifampicin.
     Colloids Surf B Biointerfaces, 60(1): 95-104. [Abstract] [Full-text]
108. Camptothecin-incorporating N-phthaloylchitosan-g-mPEG self-assembly micellar system: effect of degree of deacetylation.
     Colloids Surf B Biointerfaces, 60(1): 117-24. [Abstract] [Full-text]
109. The effects of preoperative chemotherapy on isolated tumour cells in the blood and bone marrow of gastric cancer patients.
     Br J Cancer, 97(5): 589-92. [Abstract] [Full-text]
110. Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study.
     Br J Cancer, 97(5): 582-8. [Abstract] [Full-text]
111. Intratumoural injection of the toll-like receptor-2/6 agonist 'macrophage-activating lipopeptide-2' in patients with pancreatic carcinoma: a phase I/II trial.
     Br J Cancer, 97(5): 598-604. [Abstract] [Full-text]
112. Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma.
     Br J Cancer, 97(5): 593-7. [Abstract] [Full-text]
113. Does small-cell phenotype predict the natural history of prostate cancer? A case study in disease behavior.
     Nat Clin Pract Oncol, 4(9): 551-4. [Abstract] [Full-text]
114. PEGylated bioactive molecules in biodegradable polymer microparticles.
     Expert Opin Biol Ther, 7(9): 1427-36. [Abstract] [Full-text]
115. Phase II trial of chemoradiation for organ preservation in resectable stage III or IV squamous cell carcinomas of the larynx or oropharynx: results of Eastern Cooperative Oncology Group Study E2399.
     J Clin Oncol, 25(25): 3971-7. [Abstract] [Full-text]
116. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer.
     J Clin Oncol, 25(25): 3965-70. [Abstract] [Full-text]
117. Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma.
     J Clin Oncol, 25(25): 3958-64. [Abstract] [Full-text]
118. Epidermal growth factor receptor mutation status and adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung.
     J Clin Oncol, 25(25): 3952-7. [Abstract] [Full-text]
119. Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy.
     J Clin Oncol, 25(25): 3930-5. [Abstract] [Full-text]
120. Brain structure and function differences in monozygotic twins: possible effects of breast cancer chemotherapy.
     J Clin Oncol, 25(25): 3866-70. [Abstract] [Full-text]
121. Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy.
     J Clin Oncol, 25(25): 3802-7. [Abstract] [Full-text]
122. Saline or albumin for fluid resuscitation in patients with traumatic brain injury.
     N Engl J Med, 357(9): 874-84. [Abstract] [Full-text]
123. Side effects of HIV therapy.
     J Dtsch Dermatol Ges, 5(9): 745-54. [Abstract] [Full-text]
124. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.
     J Clin Oncol, 25(25): 3884-91. [Abstract] [Full-text]
125. A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer.
     J Clin Oncol, 25(25): 3816-22. [Abstract] [Full-text]
126. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.
     J Clin Oncol, 25(25): 3892-901. [Abstract] [Full-text]
127. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer.
     J Clin Oncol, 25(25): 3853-8. [Abstract] [Full-text]
128. Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease.
     J Clin Oncol, 25(25): 3902-7. [Abstract] [Full-text]
129. Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk.
     J Clin Oncol, 25(25): 3871-6. [Abstract] [Full-text]
130. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects.
     J Clin Oncol, 25(25): 3991-4008. [Abstract] [Full-text]
131. Treatment of extensive subacute portal, mesenteric and ileocolic vein thrombosis with recombinant tissue plasminogen activator.
     Blood Coagul Fibrinolysis, 18(6): 581-3. [Abstract] [Full-text]
132. Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis.
     Gynecol Oncol, 106(3): 476-81. [Abstract] [Full-text]
133. Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy.
     J Infect Dis, 196(7): 1044-52. [Abstract] [Full-text]
134. Biological and therapeutic significance of MUC1 with sialoglycans in clear cell adenocarcinoma of the ovary.
     Cancer Sci, 98(10): 1586-91. [Abstract] [Full-text]

© 2004-2008 Chemotherapy Research Today. All Rights Reserved.